Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Amino Acid > Adalimumab

Adalimumab

Adalimumab is a human monoclonal antibody that binds to and neutralizes the inflammatory cytokine tumor necrosis factor-alpha (TNF-α).
It is used to treat a variety of autoimmune disorders, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.
Adalimumab works by blocking the action of TNF-α, which plays a key role in the inflammation and tissue damage associated with these conditions.
It is administered by subcutaneous injection and has been shown to effectively reduce symptoms and improve quality of life for patients with these chronic, debilitating disorders.
Reserchers can use PubCopare.ai to easily locate and compare protocols from literature, preprints, and patents to optimize their Adalimumab research and enhance reproducibility and accuracy.

Most cited protocols related to «Adalimumab»

1
Ranking Network Meta-Analysis Treatments
Cited 21 times
One of the advantages of network meta-analysis is that it can provide information about the ranking of all evaluated interventions for the studied outcome [2] (link), [42] (link). Probabilities are often estimated for a treatment being ranked at a specific place (first, second, etc.) according to the outcome.
Ranking of treatments based solely on the probability for each treatment of being the best should be avoided. This is because the probability of being the best does not account for the uncertainty in the relative treatment effects and can spuriously give higher ranks to treatments for which little evidence is available. So-called rankograms and cumulative ranking probability plots have been suggested as a reliable and comprehensive graphical way to present ranking probabilities and their uncertainty [2] (link). A rankogram for a specific treatment j is a plot of the probabilities of assuming each of the possible T ranks (where T is the total number of treatments in the network). The cumulative rankograms present the probabilities that a treatment would be among the n best treatments, where n ranges from one to T. The surface under the cumulative ranking curve (SUCRA), a simple transformation of the mean rank, is used to provide a hierarchy of the treatments and accounts both for the location and the variance of all relative treatment effects [2] (link). The larger the SUCRA value, the better the rank of the treatment.
The mvmeta command can provide ranking probabilities using the option pbest(min|max, all zero). Options min or max specify whether larger or smaller treatment effects define a better treatment, while all and zero specify the estimation of probabilities for all possible ranks including the reference treatment. The estimated probabilities can be stored as additional variables in the dataset by adding the suboption gen()in pbest() and predictive ranking probabilities (the probability that each treatment will be placed in each rank in a future study [39] (link), [40] ) can be estimated with the suboption predict.
Our STATA command sucra produces rankograms and computes SUCRA values using the ranking probabilities (e.g. as estimated with the mvmeta) as input. If prob1 prob2 etc, is a list of variables including all ranking probabilities (one variable per treatment for each possible rank) as derived from mvmeta then typing
. sucra prob*,mvmetaresultsplots the cumulative rankograms for all treatments.
In Figure 7 we present cumulative rankograms for the network of rheumatoid arthritis trials. The SUCRA values provide the hierarchy for the six active treatments; 1.8%, 59.9%, 66.2%, 21.8%, 75.9%, 41%, 83.4% for placebo, abatacept, adalimumab, anakinra, etanercept, infliximab, rituximab respectively. The cumulative rankograms can also be used to compare different models. In Figure 7 we present also the results from a network meta-regression accounting for small-study effects (using the variance of the log-odds ratios as covariate). The graph shows that small-study effects materially alter the relative effectiveness and ranking of treatments and adjustment will put etanercept and anakira in more favourable order compared with rituximab and abatacept respectively. The option compare() in the command sucra can be used to compare two ranking curves.
Chaimani A., Higgins J.P., Mavridis D., Spyridonos P, & Salanti G. (2013). Graphical Tools for Network Meta-Analysis in STATA. PLoS ONE, 8(10), e76654.
Full text: Click here
Publication 2013
Abatacept Adalimumab Anakinra Etanercept Infliximab Placebos Rheumatoid Arthritis Rituximab
2
SPIRIT-P1: Evaluating Ixekizumab and Adalimumab in Psoriatic Arthritis
Cited 16 times
The SPIRIT-P1 study (NCT01695239, EudraCT 2011-002326-49) is a 3-year, phase III, randomised, double-blind, placebo-controlled and active-controlled clinical trial comparing two regimens of ixekizumab and an active reference arm adalimumab (Humira; AbbVie) at the approved dose and regimen to treatment with placebo in patients not previously treated with biologic agents for plaque psoriasis or PsA. The double blind period of the study occurred in the first 24 weeks. Enrolled patients fulfilled the Classification Criteria for Psoriatic Arthritis (CASPAR);14 (link) had ≥3 of 68 tender joint count and ≥3 of 66 swollen joint count; and had either ≥1 PsA-related hand or foot joint erosion on centrally read X-rays or C reactive protein >6 mg/L. Further discussion of study design and patient population is included in the online supplementary material.
Mease P.J., van der Heijde D., Ritchlin C.T., Okada M., Cuchacovich R.S., Shuler C.L., Lin C.Y., Braun D.K., Lee C.H, & Gladman D.D. (2016). Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Annals of the Rheumatic Diseases, 76(1), 79-87.
Publication 2016
Adalimumab Arthritis, Psoriatic Biological Factors C Reactive Protein Dental Plaque Humira ixekizumab Joint, Foot Joints Patients Placebos Psoriasis Treatment Protocols X-Rays, Diagnostic
3
Biologic Therapies in Axial Spondyloarthritis
Cited 12 times
Participants are required to meet the Assessment of SpondyloArthritis international Society (ASAS) criteria for radiographic or non-radiographic axSpA, i.e they must satisfy at least one of the following: i) the modified New York criteria for AS [16 (link)]; ii) the imaging-based ASAS definition of axSpA [17 (link)]; or iii) the “clinical” ASAS definition of axSpA [17 (link)]. At the time of recruitment they are required to be naïve to biologic therapy. Individuals starting an “eligible” biologic therapy comprise the “biologic” cohort and those not starting a biologic therapy join the “non-biologic” cohort. The eligible drug list currently comprises adalimumab (Humira), etanercept (Enbrel) and certolizumab pegol (Cimzia). Participants must be aged at least 16 years and be willing to give informed consent for follow-up including access to medical records. Study exclusion criteria are: i) otherwise eligible patients who are starting a biologic therapy not on the eligible drug list and ii) inability to communicate in English. However, once recruited to the study, participants are eligible to remain in the study irrespective of the subsequent pharmacological or non-pharmacological management of their condition. Recruitment can take place through participating National Health Service (NHS) hospitals across the UK.
Macfarlane G.J., Barnish M.S., Jones E.A., Kay L., Keat A., Meldrum K.T., Pathan E., Sturrock R.D., Zabke C., McNamee P, & Jones G.T. (2015). The British Society for Rheumatology Biologics Registers in Ankylosing Spondylitis (BSRBR-AS) study: Protocol for a prospective cohort study of the long-term safety and quality of life outcomes of biologic treatment. BMC Musculoskeletal Disorders, 16, 347.
Full text: Click here
Publication 2015
Adalimumab Aspirin Axial Spondyloarthritis Biopharmaceuticals Certolizumab Pegol Cimzia Disease Management Enbrel Etanercept Humira Patients Pharmaceutical Preparations Radiography Spondylarthritis Therapies, Biological
4
Prospective IBD Patient Cohort Study
Cited 10 times
We recruited adult patients, age > 18 years, with CD, UC, or
indeterminate colitis in a prospective patient cohort, the prospective registry
of IBD study at Massachusetts General Hospital (PRISM). All patients were
interviewed by a study coordinator and provided detailed information regarding
their disease which was verified by their treating physician. Disease location
was classified according to the Montreal classification in CD as involving the
ileum alone, colon alone, or ileocolonic with a modifier for upper
gastrointestinal tract involvement and perianal disease. Disease behavior was
stratified as inflammatory, stricturing, or penetrating disease. Disease extent
in UC was according to the Montreal classification; patients with proctitis and
left-sided colitis were collapsed into one stratum. Smoking status was
classified as current, never, or former smoker at enrollment into the study. We
also obtained information on medication use including use of immunomodulators
(azathioprine, 6-mercaptopurine, and methotrexate) and anti-TNF agents
(infliximab, adalimumab, certolizumab pegol). Disease phenotype and medication
use was updated till August 2012. All patients provided informed consent and the
study was approved by the Institutional Review Board of Partners Healthcare.
Ananthakrishnan A.N., Huang H., Nguyen D.D., Sauk J., Yajnik V, & Xavier R.J. (2014). Differential Effect of Genetic Burden on Disease Phenotypes in Crohn’s Disease and Ulcerative Colitis: Analysis of a North American Cohort. The American journal of gastroenterology, 109(3), 395-400.
Publication 2014
Adalimumab Adult Anti-Anxiety Agents Azathioprine Behavior Disorders Certolizumab Pegol Colitis Colon Ethics Committees, Research Immunologic Adjuvants Inflammation Infliximab Mercaptopurine Methotrexate Patients Pharmaceutical Preparations Phenotype Physicians Proctitis
5
Evaluating Effectiveness of RA Treatments
Cited 9 times
After obtaining Institutional Review Board approval, we used data from a cohort of patients diagnosed with RA by a rheumatologist on the basis of the American College of Rheumatology 1987 criteria [21 (link)]. These patients were participants in the longitudinal Department of Veterans Affairs (VA) RA registry (VARA), which has been described elsewhere [22 (link)]. All VARA participants provided their written informed consent. VARA contains demographic, clinical and RA-specific information, including the Disease Activity Score using 28 joint counts (DAS28), as assessed by physicians using the DAS28 [23 (link)] and the Clinical Disease Activity Index (CDAI) [24 (link)], as well as a biorepository with banked DNA, serum and plasma. VARA data have been collected by rheumatologists at 11 VHA facilities throughout the United States since 2003. We linked VARA participants to the Veterans Health Administration's Medical SAS Datasets present in the VHA administrative databases from 2002 to 2010 to obtain medical and pharmacy claims.
Among VARA enrollees, we used claims data to identify eligible individuals in whom a biologic agent had been initiated. Biologics of interest included abatacept, adalimumab, etanercept, infliximab and rituximab. We defined "initiation" as no prior use of that biologic agent during the past 6 months. Eligible participants must have had a baseline VARA visit on the same day or within 1 month of biologic initiation. The date of initiation of the biologic (the index date) defined the start of a 1-year "treatment episode." To confirm that patients were receiving medications through the VA system, eligible individuals must have filled at least one prescription (of any duration) for any oral medication during the 6 to 12 months prior to the index date. Participants must also have had a follow-up VARA visit that occurred at 1 year ± 2 months after the index date. If there was no VARA visit at 1 year, then these treatment episodes were excluded, as there was no clinical gold standard with which to compare the algorithm's performance. VARA data were used only to capture the DAS28, the CDAI and other clinical characteristics measured at the baseline and outcome VARA visits. All other data used for the analysis were abstracted from the administrative claims data.
To test the performance of the effectiveness algorithm and to see whether it was similar for nonbiologic RA treatments, we performed a separate analysis of RA patients enrolled in VARA who were starting leflunomide (LEF), sulfasalazine (SSZ) or hydroxychloroquine (HCQ) and who also had any prior or current use of methotrexate (MTX). New MTX users were not represented in this analysis, because MTX is typically considered an "anchor" drug for RA patients and generally is continued even if the patient's therapeutic response is suboptimal, in contrast to other RA therapies, where the drugs are typically discontinued if they are not effective. Because of similarities in both the descriptive characteristics of the study populations of biologic and nonbiologic disease-modifying anti-rheumatic drug(DMARD) users and the performance characteristics of the effectiveness algorithm between biologic and DMARD treatment episodes, the data are shown throughout for the biologic users as a unique group and for a combined group of new biologic and nonbiologic DMARD users.
Curtis J.R., Baddley J.W., Yang S., Patkar N., Chen L., Delzell E., Mikuls T.R., Saag K.G., Singh J., Safford M, & Cannon G.W. (2011). Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis. Arthritis Research & Therapy, 13(5), R155.
Full text: Click here
Publication 2011
Abatacept Adalimumab Antirheumatic Drugs, Disease-Modifying Biological Factors Biopharmaceuticals DNA, A-Form Etanercept Ethics Committees, Research Gold Healthy Volunteers Hydroxychloroquine Infliximab Joints Leflunomide Methotrexate Patients Pharmaceutical Preparations Physicians Plasma Rheumatologist Rituximab Serum Sulfasalazine Veterans

Most recents protocols related to «Adalimumab»

1
Ingestible Device for Ulcerative Colitis Treatment
Not available on PMC !

Example 12

As a proof of concept, the patient population of this study is patients that (1) have moderate to severe ulcerative colitis, regardless of extent, and (2) have had an insufficient response to a previous treatment, e.g., a conventional therapy (e.g., 5-ASA, corticosteroid, and/or immunosuppressant) or a FDA-approved treatment. In this placebo-controlled eight-week study, patients are randomized. All patient undergo a colonoscopy at the start of the study (baseline) and at week 8. Patients enrolled in the study are assessed for clinical status of disease by stool frequency, rectal bleeding, abdominal pain, physician's global assessment, and biomarker levels such as fecal calprotectin and hsCRP. The primary endpoint is a shift in endoscopy scores from Baseline to Week 8. Secondary and exploratory endpoints include safety and tolerability, change in rectal bleeding score, change in abdominal pain score, change in stool frequency, change in partial Mayo score, change in Mayo score, proportion of subjects achieving endoscopy remission, proportion of subjects achieving clinical remission, change in histology score, change in biomarkers of disease such as fecal calprotectin and hsCRP, level of adalimumab in the blood/tissue/stool, change in cytokine levels (e.g., TNFα, IL-6) in the blood and tissue.

FIG. 72 describes an exemplary process of what would occur in clinical practice, and when, where, and how the ingestible device will be used. Briefly, a patient displays symptoms of ulcerative colitis, including but not limited to: diarrhea, bloody stool, abdominal pain, high c-reactive protein (CRP), and/or high fecal calprotectin. A patient may or may not have undergone a colonoscopy with diagnosis of ulcerative colitis at this time. The patient's primary care physician refers the patient. The patient undergoes a colonoscopy with a biopsy, CT scan, and/or MRI. Based on this testing, the patient is diagnosed with ulcerative colitis. Most patients are diagnosed with ulcerative colitis by colonoscopy with biopsy. The severity based on clinical symptoms and endoscopic appearance, and the extent, based on the area of involvement on colonoscopy with or without CT/MRI is documented. Treatment is determined based on diagnosis, severity and extent.

For example, treatment for a patient that is diagnosed with ulcerative colitis is an ingestible device programmed to release a single bolus of a therapeutic agent, e.g., 40 mg adalimumab, in the cecum or proximal to the cecum. Prior to administration of the treatment, the patient is fasted overnight and is allowed to drink clear fluids. Four hours after swallowing the ingestible device, the patient can resume a normal diet. An ingestible device is swallowed at the same time each day. The ingestible device is not recovered.

In some embodiments, there may be two different ingestible devices: one including an induction dose (first 8 to 12 weeks) and a different ingestible device including a different dose or a different dosing interval.

In some examples, the ingestible device can include a mapping tool, which can be used after 8 to 12 weeks of induction therapy, to assess the response status (e.g., based on one or more of the following: drug level, drug antibody level, biomarker level, and mucosal healing status). Depending on the response status determined by the mapping tool, a subject may continue to receive an induction regimen or maintenance regimen of adalimumab.

In different clinical studies, the patients may be diagnosed with Crohn's disease and the ingestible devices (including adalimumab) can be programmed to release adalimumab in the cecum, or in both the cecum and transverse colon.

In different clinical studies, the patients may be diagnosed with illeocolonic Crohn's disease and the ingestible devices (including adalimumab) can be programmed to release adalimumab in the late jejunum or in the jejunum and transverse colon.

US11857669B2. Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices (2024-01-02). BIORA THERAPEUTICS, INC. [US]. Inventors: Mitchell Lawrence Jones [US], Sharat Singh [US], Christopher Loren Wahl [US], Harry Stylli [US].
Full text: Click here
Patent 2024
Abdominal Pain Adalimumab Adrenal Cortex Hormones Biological Markers Biopsy BLOOD Cecum Colonoscopy C Reactive Protein Crohn Disease Cytokine Diarrhea Diet Endoscopy Endoscopy, Gastrointestinal Feces Homo sapiens Immunoglobulins Immunosuppressive Agents Jejunum Leukocyte L1 Antigen Complex Medical Devices Mesalamine Mucous Membrane Neoadjuvant Therapy Patient Care Management Patients Pharmaceutical Preparations Placebos Primary Care Physicians Safety Therapeutics Tissues Transverse Colon Treatment Protocols Tumor Necrosis Factor-alpha Ulcerative Colitis X-Ray Computed Tomography
2
Adalimumab PK/PD in Swine Colitis
Not available on PMC !

Example 11

The purpose of this non-Good Laboratory Practice (GLP) study is to explore the PK/PD and bioavailability of adalimumab when applied to DSS-induced colitis in Yorkshire-cross farm swine. All animals are randomized into groups of three. Animals are dosed once with adalimumab via subcutaneous (SC), perirectal (PR), or intracecal (IC) administration.

The concentration of adalimumab and TNFα is measured in plasma at 1, 2, 3, 4, 6, and 12 hours post-dose. The concentration of adalimumab is measured in rectal contents at 1, 3, 6, and 12 hours post-dose and in luminal content at 12 hours post-dose. Concentration of adalimumab and TNFα, HER2, and total protein is measured in gastrointestinal tissue, e.g., cecum sample (CAC), proximal colon sample (PCN), transverse colon sample (TCN), distal colon sample (DCNi) inflamed, distal colon non-inflamed sample (DCNn), and rectum sample (RTM), at 12 hours post-dose.

US11857669B2. Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices (2024-01-02). BIORA THERAPEUTICS, INC. [US]. Inventors: Mitchell Lawrence Jones [US], Sharat Singh [US], Christopher Loren Wahl [US], Harry Stylli [US].
Full text: Click here
Patent 2024
Adalimumab Animals Cecum Colitis Colon Drug Kinetics ERBB2 protein, human Gastrointestinal Contents Medical Devices Obstetric Delivery Phenobarbital Pigs Plasma Proteins Rectum Tissues Transverse Colon Tumor Necrosis Factor-alpha
3
Macrophage Activation and Cytokine Modulation
On day five, after cell detachment, macrophages were seeded in culture medium without M-CSF, but supplemented with the appropriate stimuli in the following concentrations: 100 ng/ml lipopolysaccharide (LPS, from Escherichia coli, Merck), 5 µg/ml Resiquimod (R848, Enzo life sciences), 100 ng/ml Pam3CSK4 (Biotechne), 5 µg/ml Polyinosinic:polycytidylic acid (poly I:C, In vivogen), 5 µg/ml CPG-c (Enzo Life sciences), 100 ng/ml interferon-gamma (IFNγ, Peprotech), 40 ng/ml interleukin-4 (IL-4, Peprotech), 20 ng/ml interleukin-13 (IL-13, Peprotech), 50 U/ml interferon beta (IFNβ, Peprotech), 20 ng/ml transforming growth factor beta (TGFβ, In vivoGen), 100 ng/ml tumor necrosis factor alpha (TNFα, Peprotech), 100 pg/ml interleukin-10 (IL-10, Peprotech). Due to the volume-per-cell difference between bulk and droplet cultures, the concentrations of stimuli in droplets were adjusted to keep the absolute amount of stimuli-per-cell constant. IL-10 receptor blocking antibodies (αIL-10R, R&D systems), were added to cultures 30 minutes prior to any other stimuli at 6 µg/ml. Cytokine neutralizing antibodies were added during stimulation at the following concentrations: 400 ng/ml IFNβ neutralizing antibody (Biotechne), 100 µg/ml TNFα neutralizing antibody (Adalimumab). Trichostatin A (Sigma Aldrich) was added 30 minutes prior to other stimuli at 1 µg/ml.
Tiemeijer B.M., Heester S., Sturtewagen A.Y., Smits A.I, & Tel J. (2023). Single-cell analysis reveals TLR-induced macrophage heterogeneity and quorum sensing dictate population wide anti-inflammatory feedback in response to LPS. Frontiers in Immunology, 14, 1135223.
Full text: Click here
Publication 2023
Adalimumab Antibodies, Blocking Antibodies, Neutralizing Cells Culture Media Cytokine Dietary Fiber Escherichia coli IL10 protein, human Interferon, beta Interferon Type II Interleukin-13 Macrophage Macrophage Colony-Stimulating Factor Poly I-C Receptor, Interleukin-10 resiquimod TNF protein, human Transforming Growth Factor beta trichostatin A
4
Retrospective Study of Advanced Therapies for IBD
This was a retrospective claim-based cohort study that utilized longitudinal claims data from the HealthCore Integrated Research Database® (HIRD®) from January 1, 2016 to August 31, 2019. The HIRD® contains data from January 2006 on patient enrollment, inpatient and outpatient medical care, prescription, and health care utilization. It is a large longitudinal medical and pharmacy claims database of health plan members comprising all regions of the US.
The data were accessed and used in full compliance with the relevant provisions of the Health Insurance Portability and Accountability Act. The study was conducted under the research provisions of Privacy Rule 45 CFR 164.514(e). Researchers’ access to claims data was limited to data stripped of identifiers to ensure confidentiality. An Institutional Review Board did not review the study since only this limited data set was accessed. This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Pharmacoepidemiology Practices as well as legal and regulatory requirements.
Adult patients aged ≥ 18 years with CD (International Classification of Diseases, 10th Revision, Clinical Modification [ICD-10-CM] diagnosis codes: K50.x) or UC (ICD-10-CM diagnosis codes: K51.x) who initiated an advanced therapy during the index period of July 1, 2016 through August 31, 2018 were included in the study. Index date was defined as the first observed occurrence of a claim (medical or pharmacy) for any eligible advanced therapy during the index period. For patients who started more than one therapy, only the earliest one observed was used. Included patients were enrolled in commercial, Medicare Advantage, or Medicare Supplemental plus Part D insurance plans for ≥ 6 months before the index date (pre-index period) and ≥ 12 months after index date (follow-up period). Eligible patients were required to have ≥ 2 medical claims for CD or UC from a provider of any specialty at least seven days apart during the study period, of which ≥ 1 claim occurred during the pre-index period.
In this study, advanced therapies for CD included TNFi (adalimumab, certolizumab, infliximab) and non-TNFi (natalizumab, ustekinumab, vedolizumab). For UC, advanced therapies included TNFi (adalimumab, golimumab, infliximab), non-TNFi (vedolizumab; ustekinumab as a potential switcher but not index drug), and other therapies (tofacitinib). Conventional therapies included 5-aminosalicylic acid derivatives (mesalazine and sulfasalazine) and immunosuppressants (azathioprine, methotrexate, mycophenolate, cyclosporine, tacrolimus, 6-mercaptopurine).
Patients were excluded if they had claims for ≥ 1 advanced therapy during the 6-month pre-index period to identify new initiators of advanced therapy. Patients who had evidence for other autoimmune diseases including psoriasis, lupus, ankylosing spondylitis, psoriatic arthritis, or rheumatoid arthritis (defined as ≥ 2 claims on different dates for the same disease) were also excluded in order to avoid misclassification of the estimated response rate (e.g., related to non-adherence) due to multiple indications.
Gibble T.H., Naegeli A.N., Grabner M., Isenberg K., Shan M., Teng C.C, & Curtis J.R. (2023). Identification of inadequate responders to advanced therapy among commercially-insured adult patients with Crohn’s disease and ulcerative colitis in the United States. BMC Gastroenterology, 23, 63.
Full text: Click here
Publication 2023
Adalimumab Adult Ankylosing Spondylitis Arthritis, Psoriatic Autoimmune Diseases Azathioprine Care, Ambulatory Certolizumab Pegol Cyclosporine derivatives Diagnosis Ethics Committees, Research golimumab Health Planning Immunosuppressive Agents Infantile Neuroaxonal Dystrophy Infliximab Inpatient Insurance, Medigap Lupus Vulgaris Mercaptopurine Mesalamine Methotrexate Natalizumab Patient Acceptance of Health Care Patients Pharmaceutical Preparations Psoriasis Rheumatoid Arthritis Sulfasalazine Tacrolimus Therapeutics tofacitinib Ustekinumab vedolizumab
5
Cost-Effectiveness of DMARD Regimens in Rheumatoid Arthritis
This prospective observational study was carried out in the Department of Pharmacology in a tertiary care institute over a period of one year after approval from the Institutional Ethics Committee (All India Institute of Medical Sciences (AIIMS), Rishikesh) (approval number AIIMS/IEC/18/160). Our study followed the principles of the Declaration of Helsinki. Subjects were recruited from patients presenting to the Rheumatology Outpatient Department (OPD) with a primary diagnosis of RA after obtaining written informed consent. Inclusion criteria were all new and previously diagnosed patients with rheumatoid arthritis based on the American College of Rheumatology (ACR) 2010 diagnostic criteria of either sex. Patients excluded from this study included those affected with arthritis due to reasons other than RA, such as vasculitis, polymyalgia rheumatica, spondyloarthropathies (reactive arthritis, ankylosing spondylitis, and psoriatic arthritis), bacterial arthritis, and fibromyalgia.
On the basis of DMARD therapy being received by the patients, they were divided into different groups: Regimen 1, monotherapy with one DMARD (methotrexate (MTX)); Regimen 2, double DMARD therapy or two DMARD therapy (methotrexate + hydroxychloroquine (MTX + HCQ)); Regimen 3, triple DMARD therapy or three DMARD therapy (methotrexate + hydroxychloroquine + leflunomide (MTX + HCQ + Lef)); and Regimen 4, >3 DMARD therapy (MTX + HCQ + Lef + bDMARD adalimumab). Patients were assessed at baseline and after the follow-up visit as per the clinician’s discretion (varying from 7 to 12 weeks). Treatment response was recorded at the baseline and follow-up visit based on the Disease Activity Score (DAS28) criteria, which comprises a number of tender joints, swollen joints, erythrocyte sedimentation rate (ESR), and “patient global health” score [10 (link)].
The medication cost of DMARD therapy was analyzed by calculating the cost of therapy per month for each patient by taking the prices from the Bureau of Pharma Public Sector Undertakings of India (BPPI), Department of Pharmaceuticals, Government of India, for all the DMARDs, except the biological drug for which the price from Cadila Healthcare Ltd. (Zydus Cadila, Ahmedabad, India) was taken. Cost-effectiveness was calculated by dividing the cost of therapy by the change in DAS in a month. Adherence was assessed using the Morisky-Green-Levine Scale (MGLS) [11 (link)]. Patients were interviewed and asked to answer four questions listed in the questionnaire on their second visit. High adherence was denoted by a score of 0, medium adherence was denoted by a score of 1 or 2, and low adherence was denoted by a score of 3 or 4. The p value was taken to be 0.05. For the cost-effective analysis, the mean was applied to the DAS28 values and the cost of treatment. Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS) software (IBM SPSS Statistics, Armonk, NY, USA).
Mittal G., Bisht M., Pai V.S, & Handu S. (2023). The Cost-Effectiveness of and Adherence to Disease-Modifying Antirheumatic Drug (DMARD) Therapy in Rheumatoid Arthritis Patients in a Tertiary Care Teaching Hospital in Uttarakhand, India. Cureus, 15(2), e34664.
Full text: Click here
Publication 2023
Adalimumab Ankylosing Spondylitis Antirheumatic Drugs, Disease-Modifying Arthritis Arthritis, Bacterial Arthritis, Psoriatic Arthritis, Reactive Biopharmaceuticals Diagnosis Fibromyalgia Institutional Ethics Committees Joints Leflunomide Methotrexate Outpatients Patients Pharmaceutical Preparations Pharmacotherapy Polymyalgia Rheumatica Public Sector Rheumatoid Arthritis Sedimentation Rates, Erythrocyte Spondylarthropathies Therapeutics Treatment Protocols Vasculitis

Top products related to «Adalimumab»

1
Humira by Abbvie
Sourced in United States, United Kingdom
Humira is a laboratory equipment product manufactured by Abbvie. It is designed to perform specific functions related to biomedical research and analysis.
2
Humira by Abbott
Sourced in United States, United Kingdom
Humira is an injectable biologic medication developed and manufactured by Abbott Laboratories. It is an antibody that targets and binds to a specific protein, tumor necrosis factor (TNF), to help reduce inflammation in the body.
3
Adalimumab by Abbvie
Sourced in United States, China
Adalimumab is a biologic medication used in the treatment of various inflammatory conditions. It functions as a monoclonal antibody that binds to and inhibits the activity of the inflammatory cytokine tumor necrosis factor alpha (TNF-α).
4
Adalimumab by Abbott
Sourced in United States
Adalimumab is a monoclonal antibody laboratory product manufactured by Abbott. It is designed to target and bind to a specific protein in the body.
5
Sas version 9 by SAS Institute
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
6
Mabthera by Roche
Sourced in Germany, Switzerland, United States
MabThera is a laboratory equipment product manufactured by Roche. It is a monoclonal antibody used for the detection and analysis of specific biological molecules.
7
Cell proliferation elisa by Roche
Sourced in Germany, Switzerland, United States, United Kingdom, Japan
The Cell Proliferation ELISA is a laboratory equipment product that measures cell proliferation. It utilizes an enzyme-linked immunosorbent assay (ELISA) technique to quantify the amount of a specific cellular marker, providing a direct assessment of cell growth and division.
8
Sodium chloride (nacl) by Merck Group
Sourced in United States, Germany, United Kingdom, India, Italy, France, Spain, China, Canada, Sao Tome and Principe, Poland, Belgium, Australia, Switzerland, Macao, Denmark, Ireland, Brazil, Japan, Hungary, Sweden, Netherlands, Czechia, Portugal, Israel, Singapore, Norway, Cameroon, Malaysia, Greece, Austria, Chile, Indonesia
NaCl is a chemical compound commonly known as sodium chloride. It is a white, crystalline solid that is widely used in various industries, including pharmaceutical and laboratory settings. NaCl's core function is to serve as a basic, inorganic salt that can be used for a variety of applications in the lab environment.
9
Acetonitrile by Thermo Fisher Scientific
Sourced in United States, United Kingdom, China, Belgium, Germany, Canada, Portugal, France, Australia, Spain, Switzerland, India, Ireland, New Zealand, Sweden, Italy, Japan, Mexico, Denmark
Acetonitrile is a highly polar, aprotic organic solvent commonly used in analytical and synthetic chemistry applications. It has a low boiling point and is miscible with water and many organic solvents. Acetonitrile is a versatile solvent that can be utilized in various laboratory procedures, such as HPLC, GC, and extraction processes.
10
Formic acid by Thermo Fisher Scientific
Sourced in United States, United Kingdom, China, Germany, Belgium, Canada, France, Australia, Spain, New Zealand, Sweden, Japan, India, Macao, Panama, Czechia, Thailand, Ireland, Italy, Switzerland, Portugal, Poland
Formic acid is a clear, colorless liquid chemical compound used in various industrial and laboratory applications. It is the simplest carboxylic acid, with the chemical formula HCOOH. Formic acid has a pungent odor and is highly corrosive. It is commonly used as a preservative, pH adjuster, and analytical reagent in laboratory settings.

More about "Adalimumab"

Adalimumab, also known by the brand name Humira, is a human monoclonal antibody that is widely used to treat a variety of autoimmune disorders.
This biologic drug works by binding to and neutralizing the inflammatory cytokine tumor necrosis factor-alpha (TNF-α), which plays a crucial role in the inflammation and tissue damage associated with conditions like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.
Adalimumab is administered via subcutaneous injection and has been shown to effectively reduce symptoms and improve quality of life for patients with these chronic, debilitating disorders.
Researchers can utilize PubCompare.ai, a powerful AI-driven platform, to easily locate and compare protocols from literature, preprints, and patents, optimizing their Adalimumab research and enhancing reproducibility and accuracy.
In addition to Adalimumab (Humira), other related terms and compounds include MabThera (Rituximab), a monoclonal antibody used to treat certain types of cancer and autoimmune disorders, as well as Cell Proliferation ELISA, a laboratory technique used to measure cell growth and proliferation.
Researchers may also encounter references to SAS version 9.4, a statistical software package, and common chemical compounds like NaCl (sodium chloride) and Acetonitrile and Formic acid, which are often used in analytical techniques.
By incorporating these related terms and concepts, researchers can better understand the broader context and applications of Adalimumab and optimize their research endeavors.